Article Archive
Lp(a) and CV risk
In epidemiological studies, levels of Lp(a) >125 nmol/L (~50 mg/dL), the 80th percentile for most populations, showed a consistent and independent positive association with CVD risk.1,2 Additionally, a large Mendelian randomisation study showed that a genetically determined doubling of Lp(a) was associated with a 22%…
read more »
About Lp(a)
Lipoprotein(a) [Lp(a)] is an LDL-like plasma lipoprotein rich in cholesterol. Lp(a) differs from LDL as it contains an additional protein, apolipoprotein(a) [apo(a)], which is attached via a single disulphide bond. Apo(a) itself comprises a series of loop structures called kringles, named after a Danish pastry….
read more »
PCSK9 – targeted therapies: new hope for homozygous FH?
Homozygous familial hypercholesterolemia (HoFH) is a rare life-threatening condition which is defined clinically by plasma cholesterol levels usually exceeding 13 mmol/L (500 mg/dL), with extensive cutaneous or tendon xanthomas and premature atherosclerosis and cardiovascular disease.1 Historically, HoFH is thought to affect about 1 in a…
read more »
